• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Vyant Bio Inc.

    2/14/22 1:04:16 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VYNT alert in real time by email
    SC 13G 1 tm226437d3_sc13g.htm SC 13G

    Schedule 13G Page 1 of 8

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Vyant Bio, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 value

    (Title of Class of Securities)

     

    92942V109

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Schedule 13GPage 2 of 8

     

    CUSIP No. 92942V109

     

      1.

    Names of Reporting Persons. FOD Capital, LLC

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b)   ¨
      3. SEC Use Only  
      4. Citizenship or Place of Organization: Florida

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:

    5. Sole Voting Power: 1,474,935
    6. Shared Voting Power:
    7. Sole Dispositive Power: 1,474,935
    8. Shared Dispositive Power:

      9. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,474,935  
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
      11.

    Percent of Class Represented by Amount in Row (9): 5.09%*

      12.

    Type of Reporting Persons (See Instructions): OO

     

    *The percentage is calculated based upon total outstanding shares of 28,989,623, as of November 9, 2021, as set forth in the Issuer’s Form 10-Q, filed on November 12, 2021.

     

    Schedule 13GPage 3 of 8

     

    CUSIP No. 92942V109

     

      1.

    Names of Reporting Persons. Michael T. Raymond

      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b)   ¨
      3. SEC Use Only  
      4. Citizenship or Place of Organization: USA

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:

    5. Sole Voting Power: 1,474,935
    6. Shared Voting Power: N/A
    7. Sole Dispositive Power: 1,474,935
    8. Shared Dispositive Power: N/A

      9. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,474,935  
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
      11.

    Percent of Class Represented by Amount in Row (9): 5.09%*

      12.

    Type of Reporting Persons (See Instructions): IN

     

    *The percentage is calculated based upon total outstanding shares of 28,989,623, as of November 9, 2021, as set forth in the Issuer’s Form 10-Q, filed on November 12, 2021.

     

    Schedule 13GPage 4 of 8

     

     

    Item 1. (a)Name of Issuer: Vyant Bio, Inc. (the “Issuer”)

      

    Item 1. (b)Address of Issuer's Principal Executive Offices: 2 Executive Campus, 2370 State Route 70, Suite 310, Cherry Hill, NJ 08002

     

    Item 2. (a)Name of Person Filing:

     

    This Schedule 13G is being filed by FOD Capital, LLC (“FOD Capital”) and Michael T. Raymond (the “Manager”) with regard to common stock of Vyant Bio, Inc., a Delaware corporation (the “Issuer”). FOD Capital is a family investment fund organized as a limited liability company under the laws of the State of Florida. The power to vote and dispose or direct the disposition of the securities of the issuer on behalf of FOD Capital is vested in Mr. Raymond, as portfolio manager. As of the date of signing of this report, Mr. Raymond, as the Manager of FOD Capital, has the sole power to vote and dispose or direct the disposition of 1,474,935 shares of common stock (or securities convertible into common stock) of the Issuer owned by FOD Capital.

      

    Item 2. (b)Address of Principal Business Office or, if none, Residence:

     

    The principal business office of FOD Capital, LLC. is located at:

     

    7009 Shrimp Road

    Suite 4

    Key West, FL 33040

     

    The principal business office of Michael T. Raymond is located at:

     

    Michael T. Raymond

    2600 W. Big Beaver Rd.

    Suite 300

    Troy MI 48084

     

    Item 2. (c)Citizenship: FOD Capital is a limited liability company organized under the laws of the State of Florida. Mr. Raymond is a citizen of the United States of America.

     

    Item 2. (d)Title of Class of Securities: Common Stock

      

     

    Schedule 13GPage 5 of 8

     

     

    Item 2. (e)CUSIP Number: 92942V109

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not Applicable.

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

     

    (k)¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

    FOD Capital -- 1,474,935

    Mr. Raymond -- 1,474,935

     

    (b)Percent of class:

    FOD Capital -- 5.09%*

    Mr. Raymond -- 5.09%*

     

     

    Schedule 13GPage 6 of 8

     

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

    FOD Capital -- 1,474,935

    Mr. Raymond -- 1,474,935

     

    (ii)Shared power to vote or to direct the vote: N/A

     

    (iii)Sole power to dispose or to direct the disposition of:

    FOD Capital -- 1,474,935

    Mr. Raymond -- 1,474,935

     

    (iv)Shared power to dispose or to direct the disposition of: N/A

     

     

    *The percentage is calculated based upon total outstanding shares of 28,989,623, as of November 9, 2021, as set forth in the Issuer’s Form 10-Q, filed on November 12, 2021.

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10.Certifications

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    Schedule 13GPage 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Dated: February 14, 2022

      FOD Capital, LLC
          
      By:  /s/ Michael T. Raymond
      Michael T. Raymond, Manager
          
          
      Michael T. Raymond
          
      By:  /s/ Michael T. Raymond
      Michael T. Raymond, Individually

     

     

    Schedule 13GPage 8 of 8

     

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the “Act”) by and among the parties listed below, each referred to herein as a “Joint Filer”. The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1.

     

    Dated: February 14, 2022

      FOD Capital, LLC
          
      By:  /s/ Michael T. Raymond
      Michael T. Raymond, Manager
          
          
      Michael T. Raymond
          
      By:  /s/ Michael T. Raymond
      Michael T. Raymond, Individually

      

     

     

    Get the next $VYNT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VYNT

    DatePrice TargetRatingAnalyst
    3/8/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    10/6/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VYNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Vyant Bio with a new price target

    HC Wainwright & Co. reiterated coverage of Vyant Bio with a rating of Buy and set a new price target of $4.00 from $5.00 previously

    3/8/22 6:21:03 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Vyant Bio with a new price target

    HC Wainwright & Co. initiated coverage of Vyant Bio with a rating of Buy and set a new price target of $5.00

    10/6/21 7:13:38 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Vyant Bio Inc.

    PRE 14A - Vyant Bio, Inc. (0001349929) (Filer)

    7/31/23 5:15:27 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Vyant Bio Inc.

    15-12G - Vyant Bio, Inc. (0001349929) (Filer)

    5/15/23 8:00:19 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vyant Bio, Inc. (0001349929) (Filer)

    5/10/23 8:30:11 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vyant Bio Provides Update on Winddown Activities

    CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company's stock will cease trading on the OTC, and the holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, purs

    12/26/23 9:15:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Provides Update on Winddown Activities

    CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company's common stock will cease to trade and holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at the date we file the Certificate of Dissolution to receive dist

    11/10/23 4:05:00 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Announces Stockholder Approval of Plan of Dissolution

    CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the "Special Meeting"). At the Special Meeting, Vyant Bio's stockholders, upon the unanimous recommendation of Vyant Bio's board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the "Dissolution Proposal). The proposal received the affirmative vote of holders of 94.0% of the shares casting votes and 53.1% of the Company's total outstanding common shares. Vyant Bio's Board will determin

    11/1/23 11:45:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Hansen Paul R. transferred by will 6,783 shares), increasing direct ownership by 4% to 159,778 units

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    2/27/23 5:41:18 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Hansen Paul R. was granted 4,032 shares, increasing direct ownership by 3% to 152,995 units

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    1/19/23 4:30:40 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Harris Geoffrey E. was granted 5,712 shares, increasing direct ownership by 41% to 19,761 units

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    1/19/23 4:30:27 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vyant Bio Inc. (Amendment)

    SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)

    2/14/23 8:30:50 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vyant Bio Inc.

    SC 13G - Vyant Bio, Inc. (0001349929) (Subject)

    2/14/22 1:04:16 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vyant Bio Inc. (Amendment)

    SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)

    2/11/22 7:36:40 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Leadership Updates

    Live Leadership Updates

    View All

    Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer

    Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer. Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history of scientific innovation and program leadership at the int

    10/26/21 8:00:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Financials

    Live finance-specific insights

    View All

    Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights

    Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou FoundationEntered into a master services agreement and related statement of work with an Australian CRO in November 2022 to support the Company's adult Rett Syndrome clinical trialProgress with licensing our iPSC technology to transition key product sales customers Q3 2022 Financial Highlights $9.4 million of cash and equivalents as of September 30, 2022Current cash balances, net proceeds from the sale of

    11/15/22 8:00:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary

    ~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology's Capabilities to Provide Customers with Solutions in Both the Discovery and Development of New Drug Candidates ~ ~ Transaction Provides Vyant Bio with Additional Capital to Deploy into Further Development of its Therapeutic Pipeline in Genetic CNS Disorders ~ MALVERN, PA and CHERRY HILL, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reaction Biology Corporation ("Reaction"), an industry-leading provider of drug discovery services, and Vyant Bio, Inc. ("Vyant Bio") (NASDAQ:VYNT), an innovative biotechnology company reinventing drug

    11/3/22 9:10:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

    Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 million of cash and equivalents as of June 30, 2022Cash runway approximately 18 months CHERRY HILL, N.J., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (N

    8/22/22 4:10:00 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care